If your business holds, or is applying for, a WDA(H) licence and any part of your product range includes controlled drugs, the MHRA authorisation alone does not cover you. Most wholesalers only discover this once a supplier or customer asks for evidence of a separate Home Office licence, and by then, the four to six month processing timeline has already started working against them.
This guide goes deep into what a UK Controlled Drug licence for wholesalers actually covers, how the obligations differ across Schedules 2 to 5 of the Misuse of Drugs Regulations 2001, what the Home Office genuinely checks during a compliance visit, and where wholesalers most commonly fall short. If you are searching for controlled drugs licence application UK, Home Office CD licence for wholesale dealers, Schedule 2 controlled drugs register requirements, or how to get a domestic controlled drugs licence approved, this is written for you.
Why a WDA(H) Alone Is Not Enough
A Wholesale Dealer’s Authorisation for human medicines, or WDA(H), is issued by the MHRA and covers the storage, distribution, and supply of medicines generally. But controlled drugs sit under a separate legal framework, the Misuse of Drugs Act 1971 and the Misuse of Drugs Regulations 2001, which is regulated not by the MHRA but by the Home Office.
If your WDA(H) application includes the product class for narcotic and psychotropic substances, and your business supplies any drug in Schedules 2 to 5, you need a second, entirely separate authorisation: a Home Office Domestic Controlled Drugs Licence. The two licences interrelate but are assessed independently, by different regulators, with different named persons, different inspection standards, and different renewal cycles.
- A retail pharmacy business does not usually need a controlled drugs licence, because certain limited exemptions apply under the Misuse of Drugs Regulations 2001
- A wholesaler, importer, exporter, or producer of Schedule 2 to 5 controlled drugs almost always does
- If your business already holds, or is applying for, a WDA(H), and controlled drugs form any part of your supply activity, a Home Office CD licence becomes a parallel legal requirement, not an optional extra
Businesses that assume their MHRA licence covers controlled drugs by default are one of the most common groups to fall foul of this rule, often only realising the gap when a customer requests proof of the Home Office licence before placing an order.
How the Application Process Works
Applications are submitted through the Home Office’s Controlled Drugs Licensing System, which requires registration as a customer before you can start a licence application. The process includes several stages that wholesalers frequently underestimate:
- Every person named on the licence must undergo a Disclosure and Barring Service, or DBS, check before the application can progress
- The Home Office typically names four key roles on a licence application, and each person in those roles carries personal legal accountability, not just administrative responsibility
- Once DBS checks are confirmed, the Home Office arranges a compliance visit to the site before any licence is granted
- Applicants must specify whether they need a domestic licence, for UK-only supply, or an import and export licence, or both, depending on the scope of activity
Processing timelines are longer than most applicants expect. Home Office guidance and sector consultants both put the realistic timeline at up to four months for most straightforward domestic applications, and official guidance from bodies overseeing licensed premises now states it can take at least six months from application to decision, even when the applicant has everything ready at the point of submission. If you are applying for a WDA(H) and a CD licence at the same time, these timelines run in parallel but rarely finish together, so sequencing your product launch or supply agreements around the slower of the two licences is essential.
One detail that rarely gets covered: if you already hold a CD licence and are applying for a replacement covering the same schedules and activities, with no change to the details on your current licence, you may continue operating under your existing licence’s conditions while the replacement application is being considered. This continuity provision only holds if nothing else on the licence has changed, which makes it critical to flag any site, personnel, or activity changes separately rather than folding them into a routine renewal.
Understanding Schedules 2 to 5: What Actually Changes
This is where most wholesalers get their compliance planning wrong. The five schedules under the Misuse of Drugs Regulations 2001 are not a simple sliding scale of “more paperwork for higher schedules.” Each schedule carries a distinct combination of licensing, safe custody, record keeping, and destruction requirements, and treating them all the same way is one of the fastest routes to a compliance finding.
Schedule 2
Schedule 2 covers drugs with recognised therapeutic value but high potential for misuse, including diamorphine, morphine, ketamine, and pethidine. For wholesalers, this is the strictest tier:
- Full controlled drug requirements apply to prescriptions, safe custody, and record keeping
- All receipt, supply, and disposal activity must be recorded in a Controlled Drug register, maintained in line with the Misuse of Drugs (Safe Custody) Regulations 1973
- Storage must be in a dedicated CD cabinet or safe that meets the safe custody regulation, typically constructed to a recognised standard with a multi-point locking mechanism
- Registers must be retained for a minimum of two years from the date of the last entry, though many businesses retain them for considerably longer as standard policy
- Stock discrepancies between the physical count and the register are treated as one of the most serious findings during any compliance inspection, so regular reconciliation is not optional
Schedule 3
Schedule 3 includes drugs such as temazepam, midazolam, and buprenorphine, and sits in a genuinely inconsistent middle ground that catches many wholesalers out:
- Safe custody requirements apply to most Schedule 3 drugs, but some are specifically exempt, midazolam being a commonly cited example
- Unlike Schedule 2, there is generally no legal requirement to record Schedule 3 transactions in a CD register, although many businesses choose to log them anyway as good practice
- Regulation 24 of the Misuse of Drugs Regulations 2001 requires invoices for Schedule 3 controlled drugs to be retained for two years
- Because the exemptions within Schedule 3 are drug-specific rather than blanket, wholesalers need a product-level reference, not a single Schedule 3 policy, to stay compliant
Schedule 4
Schedule 4 is split into two parts and covers drugs including most benzodiazepines and anabolic steroids:
- No CD register entry is required
- No additional safe custody requirement applies beyond standard secure medicines storage
- Requirements are broadly similar to standard prescription-only medicines in terms of storage and record keeping
- The practical compliance burden is significantly lighter than Schedules 2 and 3, which is precisely why some businesses become complacent about controls that still apply elsewhere in their licence
Schedule 5
Schedule 5 covers preparations containing very low strength controlled substances, and carries the lightest obligations of the five schedules:
- No legal requirement for locked cabinet storage
- No CD register entry required
- Invoices must still be retained for two years under Regulation 24
- No specific legal destruction requirements beyond general good practice
A useful reference point that almost never gets mentioned outside specialist guidance: NICE recommends retaining invoices for all controlled drugs, across every schedule, for six years, which goes well beyond the statutory two-year minimum under Regulation 24. Wholesalers who set their document retention policy purely to the legal minimum often find themselves unable to produce records during a later audit or a supply chain investigation, simply because their internal policy expired before regulators or customers came asking.
Where Wholesalers Commonly Fall Short
Beyond the schedule-specific detail above, a handful of patterns show up repeatedly during Home Office and MHRA joint scrutiny of controlled drug wholesalers:
- Treating all controlled drugs under one blanket internal SOP instead of a schedule-specific and, where relevant, drug-specific procedure
- Failing to separate the key roles on a CD licence from the Responsible Person role required under the WDA(H), even though the two regulators expect distinct accountability
- Allowing DBS checks to lapse or become outdated for named individuals, which stalls both new applications and variations
- Under-resourcing the reconciliation process for Schedule 2 stock, leading to discrepancies that trigger deeper scrutiny of the entire site
- Assuming a licence renewal is routine and failing to flag site, personnel, or activity changes separately, which can invalidate the continuity provision that lets a business keep trading under its existing licence while a renewal is processed
- Retaining records only to the statutory two-year minimum rather than building in the longer retention window that NICE guidance and most regulators expect to see in practice
Practical Steps Before You Apply
- Confirm early whether your product range actually falls under Schedules 2 to 5, since misclassifying a product is one of the most common reasons applications stall
- Register on the Controlled Drugs Licensing System and start DBS checks for all named individuals well before you plan to submit
- Build a schedule-specific SOP rather than a single generic controlled drugs policy, with explicit exemptions noted at the product level for Schedule 3
- Set your document retention policy to at least six years across all schedules rather than the statutory two-year minimum
- Align your WDA(H) and CD licence timelines from the outset, since the two applications rarely complete on the same schedule
- Treat any change to site, personnel, or activity as a standalone notification rather than bundling it into a routine renewal
How Quality and Vigilance Ltd Can Help
This is precisely the kind of dual-regulator compliance work that Quality and Vigilance Ltd supports clients through, alongside its core pharmacovigilance and regulatory affairs remit covering EMA, FDA, and MHRA requirements. Controlled drug wholesaling sits at the intersection of MHRA GDP expectations and Home Office licensing law, and getting the schedule-specific detail wrong on either side can delay a licence by months or trigger a serious compliance finding once you are already trading. For businesses preparing a Home Office CD licence application alongside a WDA(H), varying an existing controlled drugs licence, or building out schedule-specific SOPs that will actually hold up during a compliance visit, here is where experienced regulatory support genuinely earns its cost:
- Structuring a compliant, schedule-specific SOP before submission rather than retrofitting one after a deficiency letter
- Coordinating WDA(H) and Home Office CD licence timelines so neither application blocks the other
- Reviewing named-person accountability across both licences to close the gap regulators most often flag
- Setting up record retention and reconciliation processes that meet both the statutory minimum and current best-practice expectations
Get in touch with Quality and Vigilance Ltd today to get your controlled drugs licence application built right the first time.